Abstract: Disclosed herein are activatable conductive compositions and methods of making and using activatable conductive compositions. In particular, activatable conductive monomers polymers are described and electrically conductive coatings that include activatable conductive polymers.

Abstract: Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed.

Abstract: Methods of allocating raters to assessment visits of studies, and tangible computer readable media including software that is adapted to control a computer to implement methods of allocating raters to assessment visits of studies, are provided. Raters are allocated by retrieving blinding information that includes at least one blinding criterion for a visit of a study, retrieving rater information for at least one rater associated with the study, comparing the retrieved rater information and the retrieved blinding information to identify one or more raters meeting the at least one blinding criterion and enabling selection of the identified one or more raters for allocation to the visit of the study. A rater may then be allocated to the visit by receiving a selection for at least one of the identified raters and allocating the at least one rater to the visit responsive to the received selection.

Abstract: Embodiments of the invention include devices and methods for delivery of nucleic acids as active agents. Embodiments of the invention include devices and methods for delivery of nucleic acids as active agents. In an embodiment, an article for delivering an active agent is included. The article can include a dehydrated complex including a nucleic acid, a transfection agent, and a saccharide protectant. The nucleic acid and transfection agent can form a liposome or a lipoplex. The dehydrated complex can be disposed within a polymeric matrix. The dehydrated complex can be disposed within a microparticle. Other embodiments are also included herein.

Abstract: Embodiments of the invention include devices and methods for the release of nucleic acid complexes. In an embodiment the invention includes a nucleic acid delivery particle. The delivery particle can include a polymeric matrix including a polyethyleneglycol containing copolymer and a nucleic acid complex disposed within the polymeric matrix. The nucleic acid complex can include a nucleic acid and a carrier agent. In an embodiment the invention includes a medical device including a first polymeric matrix comprising a first polymer and a plurality of nucleic acid delivery particles disposed within the first polymeric matrix. The medical device can be configured to release the nucleic acid complex when the medical device is implanted within a subject. Other embodiments are included herein.

Abstract: A tank truck is provided for collecting and transporting flowable material. The tank truck may include a tank configured to store flowable material, a retractable suction hose assembly connected to the tank and supported by a retractable boom, the suction hose assembly including an arrangement of telescoping tubes and a hose, and a drive assembly for selectively adjusting the horizontal and vertical position of the suction hose.

Abstract: Embodiments of the invention include devices for the release of nucleic acids and related methods. In an embodiment, the invention includes an active agent eluting coating including a polymeric matrix, a cationic carrier agent disposed with the matrix, and an active agent disposed within the matrix, the active agent including nucleic acids substantially uncomplexed with the cationic carrier agent. In an embodiment, the invention includes a method of making an implantable medical device including selecting a concentration of a cationic carrier agent corresponding to a desired elution profile, combining a matrix forming polymer, an active agent, a solvent, and the cationic carrier agent to form a coating composition having the selected concentration of the cationic carrier agent, the active agent comprising nucleic acids, and depositing the coating composition onto the surface of a substrate. Other embodiments are included herein.

Abstract: Embodiments of the invention include devices and methods for the controlled elution of nucleic acid delivery complexes. In an embodiment, the invention includes a medical device including a substrate surface, a polymeric coating disposed on the surface, the polymeric coating coupled to the substrate surface through the reaction product of a photoreactive group; the polymeric coating comprising negatively charged species on the surface; and a plurality of nucleic acid delivery complexes disposed on the polymeric coating, the nucleic acid delivery complexes comprising a nucleic acid and a cationic carrier agent complexed to the nucleic acid. Other embodiments are included herein.

Abstract: Methods of allocating raters to assessment visits of studies, and tangible computer readable media including software that is adapted to control a computer to implement methods of allocating raters to assessment visits of studies, are provided. Raters are allocated by retrieving blinding information that includes at least one blinding criterion for a visit of a study, retrieving rater information for at least one rater associated with the study, comparing the retrieved rater information and the retrieved blinding information to identify one or more raters meeting the at least one blinding criterion and enabling selection of the identified one or more raters for allocation to the visit of the study. A rater may then be allocated to the visit by receiving a selection for at least one of the identified raters and allocating the at least one rater to the visit responsive to the received selection.

Abstract: Embodiments of the invention include devices and methods for the controlled elution of nucleic acid delivery complexes. In an embodiment, the invention includes a method of making a medical device. The method can include complexing nucleic acids with a carrier agent to form a delivery complex solution, applying the delivery complex solution to a substrate, and applying a polymeric solution to the substrate. In another embodiment, the invention includes a method of making a medical device including complexing nucleic acids with a carrier agent to form nucleic acid delivery complexes, combining the nucleic acid delivery complexes with a polymer solution and a cross-linking agent, wherein the cross-linking agent is positively charged or charge neutral.

Abstract: A timeout helper main thread is created for an outbound call associated with a container. The main thread creates a timeout helper worker thread. A local timer is started to detect a first timeout condition based on a first timeout interval. The worker thread initiates a client Object Request Broker (ORB) to detect a second timeout condition based on a second timeout interval. If the outbound call completes within the first timeout interval, a result object is returned from the main thread. Otherwise, the main thread throws a timeout exception. If the outbound call has not completed within the second timeout interval, the client ORB throws an exception to the worker thread and one or more resources associated with the outbound call are reclaimed. As an alternative to the client ORB, an HTTP client can detect the second timeout condition.

Abstract: The present invention relates to compounds that are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.

Abstract: A high temperature hot strength magnesia-based refractory composition having high durability at elevated temperatures wherein a sulfamic acid in combination with an independent calcia source is added to a magnesia-based refractory material. The invention also provides for a refractory gunning composition for use in the production or repair of metallurgical furnace linings.

Abstract: A method is provided for use of a concrete composition and an associated apparatus. The method provides for mixing of the concrete material, accelerant powder and, optionally, an associated substance to enable the controlled hardening of the concrete material in a monolithic structure. The apparatus can dispose a slip-plane film to facilitate a relatively continuous process.

Abstract: A method is provided for use of a concrete composition and an associated apparatus. The method provides for mixing of the concrete material, accelerant powder and, optionally, an associated substance to enable the controlled hardening of the concrete material in a monolithic structure. The apparatus can dispose a slip-plane film to facilitate a relatively continuous process.

Abstract: A method is provided for use of a concrete composition and an associated apparatus. The method provides for mixing of the concrete material, accelerant powder and, optionally, an associated substance to enable the controlled hardening of the concrete material in a monolithic structure. The apparatus can dispose a slip-plane film to facilitate a relatively continuous process.

Abstract: Described is a method for analysing DNA of a sweet potato, characterised in by the following steps:

Abstract: In a telephone system employing a PBX server to communicate with local telephones over a local area network, fallback adapters are provided to automatically respond to a power failure and also respond to the failure of the PBX server to automatically connect the telephones directly to a telephone line. This automatic connection enables the telephones to be used as analog phones and make and receive calls directly without using the PBX server. Power failure is detected by relays which default to a position to connect the telephones directly to the telephone line. The fallback detectors have controller logic which detects the presence of a ringing signal on the telephone line and the failure of the PBX to respond to the ringing signal. In addition, the fallback detectors detect the failure of the PBX to respond when a telephone is used to attempt to make an outgoing call or a call to another one of the local telephones.

Abstract: An imaging system coupled to a network, the network coupling imaging devices of at least first and second different imaging modalities, each modality including functions which are common to each of the first and second modalities, includes an imaging device, a network coupling the imaging device to a remote facility, an interface associated with the imaging device, and a pointing device for moving a pointer icon about the display and for selecting displayed icons. The network provides the imaging device with remote services from the remote facility. The interface includes a display and a programmed data processor for providing a uniform interface image on the display despite the specific modality.

Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a 5HT1D receptor antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a 5HT1D receptor antagonist.